在FF/UMEC/VI开始治疗后,COPD患者口服皮质类固醇使用的变化
Michael Bogart1, Carl B Abbott2, Mohan Bangalore3
1US Value Evidence and Outcomes, GSK, Durham, NC, USA.
International journal of chronic obstructive pulmonary disease
|November 7, 2023
概括
弗卢蒂卡松酸/尤克利迪尼/维兰特醇 (FF/UMEC/VI) 在慢性阻塞性肺病 (COPD) 患者中显著减少了口服皮质类固醇 (OCS) 的使用和医疗保健访问. 这项现实研究表明,FF/UMEC/VI改善了OCS依赖性COPD患者的治疗结果.
科学领域:
- 肺部医学 肺部医学
- 药物治疗 药物治疗
- 现实世界的证据 现实世界的证据
背景情况:
- 口服皮质类固醇 (OCS) 用于急性慢性阻塞性肺病 (COPD) 恶化,但在长期使用时存在风险.
- 有限的数据存在于流动松酸/umeclidinium/vilanterol (FF/UMEC/VI) 对COPD患者的OCS利用的现实影响.
- 这项研究解决了关于FF/UMEC/VI对COPD中OCS使用的影响的数据需求.
研究的目的:
- 评估启动FF/UMEC/VI对之前接受过OCS治疗的COPD患者的OCS利用率的影响.
- 评估FF/UMEC/VI启动后OCS发行,剂量和相关医疗资源利用 (HCRU) 的变化.
主要方法:
- 使用MarketScan®数据 (商业和医疗保险补充) 的回顾性数据库研究.
- 在FF/UMEC/VI启动 (索引日期) 之前,已识别的COPD患者 (≥40岁) 有≥1次OCS处方.
- 在12个月前和后的指数期内比较OCS利用率,HCRU和成本.
主要成果:
- 开始FF/UMEC/VI导致使用OCS.的患者减少了32.2%.
- 平均每名患者的OCS药房索赔减少了 (3.3至2.5),平均每日剂量减少了 (3.1至2.6毫克/天).
- 观察到与COPD相关的HCRU的显著减少,包括住院患者 (11.4%至7.1%),急诊室访问 (23.1%至17.4%) 和办公室访问 (97.5%至90.1%).
结论:
- FF/UMEC/VI启动显著减少了之前使用过OCS的COPD患者的OCS利用率.
- 该研究表明,COPD相关和所有原因的医疗保健资源利用率显著减少.
- 在COPD管理中,FF/UMEC/VI提供了一种可行的治疗选择,以减少OCS依赖和相关的医疗负担.
更多相关视频
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
01:23Inhaled Medications
287
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
287
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
310
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
310